Interpretation of the imaging was performed at an exterior core laboratory by staff who were unaware of the treatment-group assignments , medical data, and outcomes. Exterior, independent clinical monitors validated the scientific data. Statistical Analysis The trial was powered to detect a shift in the distribution of scores on the modified Rankin scale at 3 months between the intervention and control groups, with scores of 5 and 6 combined, with the assumption that the differential effect would result in a common odds ratio of just one 1.8. A complete required sample of 500 individuals was anticipated. One formal interim evaluation following the enrollment of 300 individuals was planned.20 The primary analysis was unadjusted and was performed in the intention-to-treat population.Recurrent cardiac ischemic events can be due to recurrence at the initial treatment site, the presence of untreated lesions elsewhere, or progressive lesions. However, potential, systematic data on the origin of recurrent events are lacking. Moreover, retrospective studies have shown that most atherosclerotic plaques in charge of future acute coronary syndromes are angiographically gentle,5,6 and the lesion-related risk factors for main adverse cardiovascular events are poorly understood. Pathological studies show that thrombotic coronary occlusion after rupture of a lipid-rich atheroma with only a thin fibrous coating of intimal tissue covering the necrotic primary is the most common reason behind myocardial infarction and death from cardiac causes.7-9 However, the potential identification of thin-cap fibroatheromas is not achieved, in part because the imaging tools to recognize them in vivo did not exist until recently.